Assessment of clopidogrel responsiveness: Measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients

被引:47
|
作者
Gurbel, Paul A. [1 ]
Bliden, Kevin P. [1 ]
Etherington, Amena [1 ]
Tantry, Udaya S. [1 ]
机构
[1] Sinai Ctr Thrombos Res, Baltimore, MD 21215 USA
关键词
platelet; clopidogrel; non-responsiveness; P2Y12; receptor; maximum aggregation; late aggregation;
D O I
10.1016/j.thromres.2007.02.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Controversy surrounds the optimal platelet aggregation measurement to assess clopidogrel non-responsiveness. The P2Y12 reactivity ratio (PRR) determined by vasoditator-stimulated phosphoprotein phosphorylation levels has been used to indicate the extent of P2Y12 blockade. Objectives: We sought to compare the prevalence of non-responsiveness measured by maximum (MA) and 6 min aggregation (FA) and correlate these measurements with PRR in patients with non-responsiveness. Methods: MA and FA were measured in stented patients (n = 100) before and after clopidogrel treatment. The PRR was determined in 22 non-responsive patients. Responsiveness was defined as pre-treatment minus post-treatment aggregation; and non-responsiveness was defined as < 10% change in platelet aggregation. Results: Responsiveness was greater as determined by FA, p=0.006 (5 PM ADP) and p=0.003 (20 mu M ADP)). There was a strong correlation between MA and FA stimulated by 5 mu M (r=0.84, p < 0.0001) and 20 mu M ADP (r=0.90, p < 0.001). The prevalence of non-responsiveness rose with agonist concentration but did not differ significantly between methods: 5 mu M ADP [22% (MA) vs. 17% (FA), p = 0. 186] and 20 mu M ADP [33% (MA) vs. 29% (FA), p=0.270]. PRR correlated with both MA (r=0.66, p < 0.001) and FA (r= 0.74, p < 0.001) in non-responsive patients indicating incomplete receptor blockade. Conclusion: Clopidogrel responsiveness is higher when measured by FA as compared to
引用
收藏
页码:107 / 115
页数:9
相关论文
共 50 条
  • [41] Effects of colchicine on platelet aggregation in patients on dual antiplatelet therapy with aspirin and clopidogrel
    Plinio Cirillo
    Vittorio Taglialatela
    Grazia Pellegrino
    Andrea Morello
    Stefano Conte
    Luigi Di Serafino
    Giovanni Cimmino
    Journal of Thrombosis and Thrombolysis, 2020, 50 : 468 - 472
  • [42] Clopidogrel inhibits platelet aggregation in patients on aspirin with stable chronic angina pectoris
    Saha, Samir
    Berglund, Margareta
    Sylven, Christer
    Gordon, Allan
    Agewall, Stefan
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2008, 123 (02) : 195 - 196
  • [43] A point-of-care assay to measure platelet aggregation in patients taking clopidogrel
    McLean, Dalton S.
    Cannon, Christopher P.
    FUTURE CARDIOLOGY, 2006, 2 (03) : 255 - 267
  • [44] Effects of colchicine on platelet aggregation in patients on dual antiplatelet therapy with aspirin and clopidogrel
    Cirillo, Plinio
    Taglialatela, Vittorio
    Pellegrino, Grazia
    Morello, Andrea
    Conte, Stefano
    Di Serafino, Luigi
    Cimmino, Giovanni
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2020, 50 (02) : 468 - 472
  • [45] A predominant role for cAMP-dependent protein kinase in the cGMP-induced phosphorylation of vasodilator-stimulated phosphoprotein and platelet inhibition in humans
    Li, ZY
    Ajdic, J
    Eigenthaler, M
    Du, XP
    BLOOD, 2003, 101 (11) : 4423 - 4429
  • [46] Assessment of P2Y12 Inhibition by Clopidogrel in Feline Platelets Using Flow Cytometry Quantification of Vasodilator-Stimulated Phosphoprotein Phosphorylation
    Li, Ronald H. L.
    Nguyen, Nghi
    Rosati, Tommaso
    Jandrey, Karl
    FRONTIERS IN VETERINARY SCIENCE, 2020, 7
  • [47] The effect of clopidogrel besylate and clopidogrel hydrogensulfate on platelet aggregation in patients with coronary artery disease: A retrospective study
    Borsiczky, Balazs
    Sarszegi, Zsolt
    Konyi, Attila
    Szabados, Sandor
    Gaszner, Balazs
    THROMBOSIS RESEARCH, 2012, 129 (06) : 700 - 703
  • [48] Palmatine Derivatives as Potential Antiplatelet Aggregation Agentsvia Protein Kinase G/Vasodilator-Stimulated Phosphoprotein andPhosphatidylinositol 3-Kinase/Akt Phosphorylation
    Fan, Tianyun
    Cheng, Yangyang
    Wei, Wei
    Zeng, Qingxuan
    Guo, Xixi
    Guo, Zhihao
    Li, Yinghong
    Zhao, Liping
    Shi, Yulong
    Zhang, Xintong
    Jiang, Jiandong
    Wang, Yanxiang
    Kong, Weijia
    Song, Danqing
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (10) : 7399 - 7413
  • [49] Vasodilator-stimulated phosphoprotein-deficient mice demonstrate increased platelet activation but improved renal endothelial preservation and regeneration in passive nephrotoxic nephritis
    Hohenstein, B
    Kasperek, L
    Kobelt, DJ
    Daniel, C
    Gambaryan, S
    Renné, T
    Walter, U
    Amann, KU
    Hugo, CPM
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (04): : 986 - 996
  • [50] AZD6140 suppresses platelet aggregation in clopidogrel-treated patients even in those with high aggregation levels
    Store, Robert F.
    Harrington, Robert A.
    Husted, Steen
    Heptinstall, Stanley
    Wilcox, Robert G.
    Gurbel, Paul A.
    Grande, Peer
    Wickens, Mark
    Peters, Gary
    Emanuelsson, Hakan
    Cannon, Christopher P.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (09) : 208A - 208A